Research
-
New Study Finds Achieving and Maintaining Remission Can Protect Kidney Health in Lupus Nephritis
.
Posted on June 10, 2026 In a new study, researchers found achieving low disease activity or remission is possible and meaningful for people with lupus nephritis, (LN, lupus-related kidney disease) once their…
-
New Study Finds Cardiovascular Risk Control May Slow Atherosclerosis Progression in People with Systemic Lupus Erythematosus
.
Posted on June 4, 2026 A new study found that controlling traditional cardiovascular disease (CVD) risk factors, including blood pressure, cholesterol and smoking, may significantly reduce the progression of atherosclerosis in people with systemic lupus…
-
Phase 2 JASMINE Study Shows Nipocalimab Reduces Disease Activity in Adults with Systemic Lupus Erythematosus
.
Posted on June 3, 2026 Pharmaceutical company Johnson & Johnson announced new late-breaking results from its Phase 2 JASMINE study showing that investigational therapy nipocalimab significantly reduced disease activity in adults living with…
-
New Study Suggests Breath Testing Could Help Monitor Lupus Disease Activity and Fatigue
.
Posted on June 1, 2026 In a study published in the Annals of the Rheumatic Diseases researchers found that compounds detected in exhaled breath may offer a promising, noninvasive way to better…
-
New Study Finds Chronic Damage Predicts Kidney Decline in Lupus Nephritis
.
Posted on May 27, 2026 In a new study, researchers found low glomerular filtration rate (eGFR, a measure used to assess how well the kidneys filter blood) and chronic histologic damage…
-
Azathioprine Exposure Associated with Liver Condition in Systemic Lupus Erythematosus Pregnancies
.
Posted on May 25, 2026 Intrahepatic cholestasis of pregnancy (ICP) is a liver condition that can occur late (after 20 weeks) in pregnancy. A new study found a strong connection between…
-
SAPHNELO approved in the US for subcutaneous self-administration for treatment of systemic lupus erythematosus (SLE)
.
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for treatment of people living with moderately to severely active autoantibody-positive systemic lupus erythematosus (SLE). The 120 mg dose of the therapy…
-
New World Lupus Federation Global Survey Finds 58% Know Very Little or Nothing About Lupus
.
Low familiarity and ongoing misconceptions underscore the need for increased education and broader visibility, building on more than a decade of progress On May 5, 2026, he World Lupus Federation (WLF)…
-
FDA approves Gazyva® (obinutuzumab), expanding therapeutic options for treatment of adults with lupus nephritis
.
FDA approval of Gazyva expands therapeutic options for lupus care The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults…
-
Clinical Trials in Lupus Research
.
Scientists, researchers, and volunteers all have a part to play in advancing clinical trial research. It’s thanks to the collaborative efforts of these groups that we have ways to…